Thursday, 27 January 2022


Singapore's SCG Cell Therapy acquires technology from A*STAR for novel cancer treatment

13 January 2022 | News

iPSC technology to develop off-the-shelf natural killer (NK) cell therapy

Photo Credit: Freepik

Photo Credit: Freepik

Singapore-based SCG Cell Therapy has acquired the rights to human “induced pluripotent stem cell” (iPSC) technology, from the Agency for Science, Technology and Research ("A*STAR")’s Accelerate Technologies Pte Ltd (A*ccelerate).

The technology enables SCG to expand its cell therapy product portfolio and develop off-the-shelf cell-based cancer immunotherapy.

“iPSC is a technology that is derived from skin or blood cells that are reprogrammed back into an embryonic-like pluripotent state that can produce any type of human cell.

This would allow for the production of a steady source of cells for all types of cell therapy,” said Dr. Adrian Teo, Principal Investigator at A*STAR’s Institute of Molecular and Cell Biology (IMCB). SCG will use the iPSC technology to develop off-the-shelf natural killer (NK) cell therapy. 

“The advanced iPSC technology developed by A*STAR provides a promising future in mass NK cell production, offering standardized, off-the-shelf cell therapy products at a more affordable cost and more readily available to patients”, said Frank Wang Shuli, Chief Executive Officer of SCG Cell Therapy.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account